191 related articles for article (PubMed ID: 2574908)
41. Histamine H2-receptor antagonists and gastric acid secretion.
Pounder RE
Pharmacol Ther; 1984; 26(2):221-34. PubMed ID: 6152495
[No Abstract] [Full Text] [Related]
42. Omeprazole in the management of refractory duodenal ulcer.
Bardhan KD
Scand J Gastroenterol Suppl; 1989; 166():63-73. PubMed ID: 2574910
[TBL] [Abstract][Full Text] [Related]
43. Criteria for use of omeprazole in adult inpatients and outpatients.
Lajoie C
Clin Pharm; 1992 Feb; 11(2):177-9. PubMed ID: 1551300
[No Abstract] [Full Text] [Related]
44. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
45. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists.
Lundell L; Backman L; Ekström P; Enander LH; Fausa O; Lind T; Lönroth H; Sandmark S; Sandzén B; Unge P
Aliment Pharmacol Ther; 1990 Apr; 4(2):145-55. PubMed ID: 1983321
[TBL] [Abstract][Full Text] [Related]
46. [Lansoprazol].
Ponce J; Nos P
Gastroenterol Hepatol; 1995 Feb; 18(2):101-9. PubMed ID: 7621274
[No Abstract] [Full Text] [Related]
47. Histamine H2-receptor antagonists.
Pounder R
Baillieres Clin Gastroenterol; 1988 Jul; 2(3):593-608. PubMed ID: 2901868
[TBL] [Abstract][Full Text] [Related]
48. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment.
Brunner G; Creutzfeldt W; Harke U; Lamberts R
Digestion; 1988; 39(2):80-90. PubMed ID: 3410170
[TBL] [Abstract][Full Text] [Related]
49. Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.
Helman CA; Tim LO
Pharmacotherapy; 1983; 3(4):185-92. PubMed ID: 6136952
[TBL] [Abstract][Full Text] [Related]
50. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine.
Brunner G; Creutzfeldt W
Scand J Gastroenterol Suppl; 1989; 166():101-5; discussion 111-3. PubMed ID: 2513641
[TBL] [Abstract][Full Text] [Related]
51. Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2-receptor antagonists.
Koop H; Hotz J; Pommer G; Klein M; Arnold R
Aliment Pharmacol Ther; 1990 Dec; 4(6):593-9. PubMed ID: 1983342
[TBL] [Abstract][Full Text] [Related]
52. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.
Walan A; Bader JP; Classen M; Lamers CB; Piper DW; Rutgersson K; Eriksson S
N Engl J Med; 1989 Jan; 320(2):69-75. PubMed ID: 2643037
[TBL] [Abstract][Full Text] [Related]
53. Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.
Deakin M; Williams JG
Drugs; 1992 Nov; 44(5):709-19. PubMed ID: 1280563
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.
Brunner GH; Lamberts R; Creutzfeldt W
Digestion; 1990; 47 Suppl 1():64-8; discussion 76. PubMed ID: 2093018
[TBL] [Abstract][Full Text] [Related]
55. A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients.
Bamberg P; Caswell CM; Frame MH; Lam SK; Wong EC
J Gastroenterol Hepatol; 1992; 7(6):577-85. PubMed ID: 1362499
[TBL] [Abstract][Full Text] [Related]
56. Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.
Frampton JE; McTavish D
Pharmacoeconomics; 1994 Jul; 6(1):57-89. PubMed ID: 10147354
[TBL] [Abstract][Full Text] [Related]
57. Medical therapy of peptic ulcer disease.
McQuaid KR; Isenberg JI
Surg Clin North Am; 1992 Apr; 72(2):285-316. PubMed ID: 1347960
[TBL] [Abstract][Full Text] [Related]
58. Omeprazole and cimetidine in the treatment of ulcers of the body of the stomach: a double blind comparative trial. Danish Omeprazole Study Group.
BMJ; 1989 Mar; 298(6674):645-7. PubMed ID: 2496791
[TBL] [Abstract][Full Text] [Related]
59. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Langtry HD; Wilde MI
Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
[TBL] [Abstract][Full Text] [Related]
60. Acid pump blockers: what are their current therapeutic roles?
Arens MJ; Dent J
Baillieres Clin Gastroenterol; 1993 Mar; 7(1):95-128. PubMed ID: 8097414
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
